Moderna (NASDAQ:MRNA) Given New $125.00 Price Target at Royal Bank of Canada

Moderna (NASDAQ:MRNA) had its target price trimmed by Royal Bank of Canada from $160.00 to $125.00 in a research report report published on Friday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other brokerages also recently commented on MRNA. UBS Group raised their target price on shares of Moderna from $143.00 to $151.00 and gave the stock a buy rating in a report on Tuesday, May 7th. Canaccord Genuity Group boosted their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a hold rating in a research report on Friday, May 3rd. Piper Sandler reissued an overweight rating and issued a $157.00 price target (down previously from $214.00) on shares of Moderna in a research note on Friday. Needham & Company LLC reaffirmed a hold rating on shares of Moderna in a research report on Thursday. Finally, The Goldman Sachs Group dropped their target price on Moderna from $204.00 to $178.00 and set a buy rating on the stock in a research report on Friday. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Moderna has a consensus rating of Hold and a consensus price target of $126.59.

Moderna Trading Down 8.1 %

Shares of MRNA stock opened at $86.58 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. Moderna has a 12-month low of $62.55 and a 12-month high of $170.47. The firm has a fifty day moving average of $129.81 and a 200-day moving average of $115.02.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analyst estimates of $128.41 million. During the same period in the previous year, the company posted ($3.62) earnings per share. The company’s revenue for the quarter was down 29.9% on a year-over-year basis. Sell-side analysts predict that Moderna will post -7.46 EPS for the current fiscal year.

Insider Buying and Selling

In other news, President Stephen Hoge sold 255 shares of the business’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now owns 1,486,508 shares of the company’s stock, valued at $179,808,007.68. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, President Stephen Hoge sold 255 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $120.96, for a total value of $30,844.80. Following the completion of the sale, the president now directly owns 1,486,508 shares in the company, valued at $179,808,007.68. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 648 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $105,280.56. Following the transaction, the chief financial officer now owns 5,726 shares in the company, valued at approximately $930,303.22. The disclosure for this sale can be found here. In the last ninety days, insiders sold 396,239 shares of company stock valued at $55,563,937. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. TIAA Trust National Association raised its position in Moderna by 2.3% during the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Moderna by 6,528.9% during the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after buying an additional 381,808 shares during the last quarter. Allworth Financial LP boosted its stake in Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after buying an additional 101 shares in the last quarter. Cadinha & Co. LLC grew its position in Moderna by 109.0% in the fourth quarter. Cadinha & Co. LLC now owns 81,838 shares of the company’s stock valued at $8,139,000 after acquiring an additional 42,685 shares during the last quarter. Finally, Stratos Wealth Advisors LLC raised its stake in Moderna by 32.3% during the fourth quarter. Stratos Wealth Advisors LLC now owns 4,003 shares of the company’s stock worth $398,000 after acquiring an additional 978 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.